論文

査読有り 国際誌
2020年4月28日

Transcription factor MafB in podocytes protects against the development of focal segmental glomerulosclerosis.

Kidney international
  • Toshiaki Usui
  • Naoki Morito
  • Hossam H Shawki
  • Yoshinori Sato
  • Hiroyasu Tsukaguchi
  • Michito Hamada
  • Hyojung Jeon
  • Manoj Kumar Yadav
  • Akihiro Kuno
  • Yuki Tsunakawa
  • Risa Okada
  • Takaaki Ojima
  • Maho Kanai
  • Keigo Asano
  • Yuki Imamura
  • Ryusuke Koshida
  • Keigyou Yoh
  • Joichi Usui
  • Hideki Yokoi
  • Masato Kasahara
  • Ashio Yoshimura
  • Masafumi Muratani
  • Takashi Kudo
  • Hisashi Oishi
  • Kunihiro Yamagata
  • Satoru Takahashi
  • 全て表示

98
2
開始ページ
391
終了ページ
403
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.kint.2020.02.038

Focal segmental glomerulosclerosis (FSGS) is a common cause of steroid-resistant nephrotic syndrome. Spontaneous remission of FSGS is rare and steroid-resistant FSGS frequently progresses to renal failure. Many inheritable forms of FSGS have been described, caused by mutations in proteins that are important for podocyte function. Here, we show that a basic leucine zipper transcription factor, MafB, protects against FSGS. MAFB expression was found to be decreased in the podocytes of patients with FSGS. Moreover, conditional podocyte-specific MafB-knockout mice developed FSGS with massive proteinuria accompanied by depletion of the slit diaphragm-related proteins (Nphs1 and Magi2), and the podocyte-specific transcription factor Tcf21. These findings indicate that MafB plays a crucial role in the pathogenesis of FSGS. Consistent with this, adriamycin-induced FSGS and attendant proteinuria were ameliorated by MafB overexpression in the podocytes of MafB podocyte-specific transgenic mice. Thus, MafB could be a new therapeutic target for FSGS.

リンク情報
DOI
https://doi.org/10.1016/j.kint.2020.02.038
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/32622525
ID情報
  • DOI : 10.1016/j.kint.2020.02.038
  • ISSN : 1523-1755
  • PubMed ID : 32622525

エクスポート
BibTeX RIS